Biotech Bay
Filter News
Found 78,943 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
2/3/2023
Personalis, Inc. and Moderna, Inc. today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform® as part of upcoming clinical studies evaluating mRNA-4157/V940.
-
The FLOW-AF multicenter, randomized controlled trial shows Ablacon's Electrographic Flow® (EGF®) Mapping software (Ablamap®) results in improved ablation outcomes in persistent atrial fibrillation
2/3/2023
Ablacon, Inc., an Ajax Health and Zeus Health-backed developer of an innovative mapping system to guide the treatment of atrial fibrillation (AF), announced today the 12-month results from the FLOW-AF trial (NCT04473963).
-
Twist Bioscience Reports Fiscal First Quarter 2023 Financial Results
2/3/2023
Twist Bioscience Corporation today reported financial results and business highlights for the first quarter of fiscal 2023 ended December 31, 2022.
-
Biotricity Selected to Present its Work on AI Enabled Stroke Prediction in CKD Patients at the 2nd Annual Innovation Showcase during the American Stroke Association 2023 International Stroke Conference
2/3/2023
Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, is excited to announce that it is one of only eight companies selected to present at the 2nd Annual Innovation Showcase during the American Stroke Association 2023 International Stroke Conference (ISC), being held in Dallas, TX.
-
Avirmax Biopharma Inc. Will Present at Glaucoma 360 New Horizons Forum 2023
2/3/2023
Avirmax Biopharma Inc. (ABI), Chief Executive and Scientific Officer, Shengjiang Shawn Liu will present the Avirmax BioPharma Inc (ABI)'s progress in the innovation and development of genetic medicines for glaucoma treatment at Glaucoma 360 New Horizons Forum at The Westin St. Francis in San Francisco, Feb 03, 2023.
-
Structure Therapeutics Announces Pricing of Upsized Initial Public Offering
2/3/2023
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the pricing of its upsized initial public offering of 10,740,000 American depositary shares (ADSs), each representing three ordinary shares, at a public offering price of $15.00 per ADS.
-
Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 Tissue
2/2/2023
Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360 ® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.
-
Varian Receives FDA 510(k) Clearance for Halcyon and Ethos Radiotherapy Systems Featuring HyperSight Imaging Solution and Announces First Patient Treatment
2/2/2023
Varian, a Siemens Healthineers company, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), as well as CE mark, for Halcyon® and Ethos™ radiotherapy systems featuring Varian's HyperSight™ imaging solution.
-
4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema
2/2/2023
4D Molecular Therapeutics (Nasdaq: FDMT, “4DMT”), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced FDA clearance of the Investigational New Drug Application (IND) for 4D-150, an R100 vector-based intravitreal genetic medicine, for the treatment of patients with Diabetic Macular Edema (DME).
-
Rigel Announces Publication of REZLIDHIA™ (olutasidenib) Phase 2 Clinical Results in Blood Advances
2/2/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication of data in Blood Advances, which summarizes clinical results from the Phase 2 registrational study of REZLIDHIA™ (olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1)1, in patients with mIDH1 relapsed or refractory acute myeloid leukemia (R/R AML).
-
Nova Scotia Health Partners with Medable for Decentralized Clinical Trial Technology to Improve Oncology Patient Access
2/2/2023
Medable Inc., the leading technology platform for clinical trials, announced that its decentralized clinical trial (DCT) platform was selected by the Nova Scotia Health Innovation Hub to increase the accessibility of oncology care for remote patients in rural Nova Scotia, with the long-term aim to improve patient access and trial diversity across Canada.
-
Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors
2/2/2023
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for PLN-101095, an oral, small molecule, dual selective inhibitor of integrins αvβ8 and αvβ1.
-
Qvin™ Menstrual Blood Diagnostic Device Receives FDA Approval in Thailand
2/2/2023
Qvin™, the biotechnology company that developed the first and only healthcare service that scientifically collects menstrual blood to test for HR-HPV and other critical healthcare information, announced FDA approval in Thailand for its Q-Pad technology.
-
RefleXion Receives FDA Clearance for SCINTIX Biology-Guided Radiotherapy; Cutting-edge Treatment Applicable for Early and Late-stage Cancers
2/2/2023
RefleXion Medical, a therapeutic oncology company, today announced the U.S. Food and Drug Administration (FDA) has granted the first marketing clearance for its SCINTIX™ biology-guided radiotherapy, a cutting-edge treatment applicable for early and late-stage cancers.
-
Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
2/2/2023
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced the closing of its acquisition of Pherin Pharmaceuticals, Inc., a privately held drug development company focused on neuropsychiatric and neuroendocrine conditions (Pherin).
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 02, 2023
2/2/2023
Olema Pharmaceuticals, Inc. announced that the Company granted stock options to four new employees to purchase an aggregate of 97,200 shares of the Company's common stock, effective as of February 1, 2023.
-
Exai Bio Announces Appointments of Emi Zychlinsky and Seema Singh Bhan to its Executive Leadership Team
2/2/2023
Exai Bio announced that it has added two new members to its executive leadership team — Emi Zychlinsky as Executive Vice President, Operations, and Seema Singh Bhan as Senior Advisor, Public Policy and External Affairs — to strengthen the company’s operational infrastructure and foster meaningful engagement with policymakers, regulators and advocacy organizations.
-
Ashvattha Therapeutics to Present at Upcoming Investor Conferences - February 02, 2023
2/2/2023
Ashvattha Therapeutics, a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers, to develop a new class of precision medicines, announced that the Company will provide a corporate overview at two upcoming investor conferences.
-
CooperCompanies Announces Release Date for First Quarter 2023
2/2/2023
CooperCompanies announced it will report first quarter 2023 financial results on Thursday, March 2, 2023, at 4:15 PM ET.